Mostrando 3 resultados de: 3
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
ArticleAbstract: Inhibitors of epidermal growth factor receptor (EGFR) signaling are among the novel drugs showing grPalabras claves:Autores:Bohlen P., Hicklin D., Jothy S., Kerbel R.S., Rak J., Schlaeppi J.M., Tania Crombet, Viloria-Petit A.Fuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopusShort communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
ArticleAbstract: High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas anPalabras claves:Autores:Figueredo R., Iznaga N., Lage Davila A., Menéndez A., Pérez R., Ramos M., Rodríguez V., Stevenson A., Tania Crombet, Torres F., Torres O., Veitía I.Fuentes:scopus